Heat Biologics (HTBX) Sees Large Volume Increase

Shares of Heat Biologics Inc (NASDAQ:HTBX) saw unusually-strong trading volume on Wednesday . Approximately 1,414,754 shares traded hands during mid-day trading, an increase of 233% from the previous session’s volume of 424,309 shares.The stock last traded at $2.22 and had previously closed at $2.06.

Separately, ValuEngine raised Heat Biologics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 24th.

The firm has a market capitalization of $9.32, a P/E ratio of -0.67 and a beta of 0.78.

A hedge fund recently raised its stake in Heat Biologics stock. Sabby Management LLC increased its stake in Heat Biologics Inc (NASDAQ:HTBX) by 52.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,615,123 shares of the biopharmaceutical company’s stock after acquiring an additional 902,642 shares during the quarter. Sabby Management LLC owned approximately 62.26% of Heat Biologics worth $1,001,000 at the end of the most recent quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

WARNING: This piece was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://ledgergazette.com/2018/03/14/heat-biologics-htbx-sees-large-volume-increase.html.

About Heat Biologics

Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).

Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply